Scalper1 News
Big pharmas Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) both soundly beat Q2 earnings estimates Thursday morning. Both also raised guidance, but not as much as their quarterly beats seemed to warrant. Lilly’s profit, excluding one-time items, rose 22% over the year-earlier quarter to 90 cents a share, beating analysts’ consensus by 16 cents, according to Thomson Reuters. Revenue rose 1% to $4.98 billion, where analysts had expected a slight Scalper1 News
Scalper1 News